GLP1R and chronic kidney disease: This has led to calls for research on biomarkers that identify the earliest stages of the disease, which may be termed pre-CKD in an analogy to prediabetes and pre-heart failure, two CKM conditions that share therapeutic approaches such as SGLT2I and glucagon-like peptide-1 receptor agonists (GLP1Ras) [32,33,34,35,36].